Harmony Biosciences
HRMY
202 hedge funds and large institutions have $2.24B invested in Harmony Biosciences in 2022 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 106 increasing their positions, 33 reducing their positions, and 23 closing their positions.
1,336% more call options, than puts
Call options by funds: $5.72M | Put options by funds: $398K
221% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 33
87% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 23
10% more funds holding
Funds holding: 183 → 202 (+19)
4.91% more ownership
Funds ownership: 80.7% → 85.62% (+4.9%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
4% less capital invested
Capital invested by funds: $2.34B → $2.24B (-$98.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$44.4M |
| 2 |
BlackRock
New York
|
+$40.4M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$20.5M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$17.6M |
| 5 |
Man Group
London,
United Kingdom
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
-$51.2M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$33.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$21.7M |
| 4 |
VP
venBio Partners
San Francisco,
California
|
-$15.8M |
| 5 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
-$8.61M |
HRMY Hedge Fund Activity: Q3 2022 in Review
202 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q3 2022, worth a combined $2.24B — down 4.2% from $2.34B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new HRMY positions and 23 closed out — a net gain of 20 holders — while 106 added to existing stakes and 33 trimmed.
The largest buyer was Invesco, adding an estimated $44.4M. The largest seller was Blackstone Inc, exiting entirely with an estimated $51.2M sold.
- 202 institutional investors held Harmony Biosciences (HRMY) as of Q3 2022, up from 183 in Q2 2022.
- Funds reported $2.24B of Harmony Biosciences stock for Q3 2022, down 4.2% quarter-over-quarter.
- 43 funds opened new Harmony Biosciences positions in Q3 2022 and 23 closed out, a net change of +20 holders.
- The largest Harmony Biosciences buyer in Q3 2022 was Invesco, an estimated $44.4M added.
- The largest Harmony Biosciences seller in Q3 2022 was Blackstone Inc, an estimated $51.2M sold.
Based on aggregated 13F filings for Q3 2022.